Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease

J Med Chem. 2009 Apr 23;52(8):2163-76. doi: 10.1021/jm900064c.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / enzymology
  • Amyloid Precursor Protein Secretases / antagonists & inhibitors
  • Animals
  • Antiviral Agents / chemical synthesis*
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Biological Products / chemical synthesis*
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Darunavir
  • Drug Design
  • Drug Discovery
  • Drug Resistance, Viral
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • HIV Infections / drug therapy*
  • HIV Infections / enzymology
  • HIV Protease Inhibitors / chemical synthesis
  • HIV Protease Inhibitors / chemistry
  • HIV Protease Inhibitors / pharmacology
  • HIV-1 / enzymology
  • Humans
  • Molecular Mimicry
  • Molecular Structure
  • Peptides / chemistry
  • Structure-Activity Relationship
  • Sulfonamides / chemical synthesis
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use

Substances

  • Antiviral Agents
  • Biological Products
  • Enzyme Inhibitors
  • HIV Protease Inhibitors
  • Peptides
  • Sulfonamides
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • BACE1 protein, human
  • Darunavir